A 2024 scientific update on the clinical performance of drug-coated balloons.

ABSTRACT: Continuous advances in the field of interventional cardiology have led to the development of drug-coated balloons (DCB). These represent a promising device for overcoming the well-known limitations of traditional metallic stents, which are associated with a persistent yearly increased risk of adverse events. This technology has the ability to homogeneously transfer the drug into the vessel wall in the absence of a permanent prosthesis implanted in the coronary vessel. Robust data support the use of DCB for the treatment of in-stent restenosis, but there is also currently growing evidence from long-term follow-up of large randomised clinical trials regarding the use of these devices in other scenarios, such as de novo small and large vessel disease, complex bifurcations, and diffuse coronar

SUBMITTER: Lazar FL 

PROVIDER: S-EPMC10900242 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature